Research progress of the application of anti-CD 20 monoclonal antibodies in the treatment of primary nephrotic syndrome in children
10.3760/cma.j.cn101070-20220406-00369
- VernacularTitle:抗CD 20单抗治疗儿童原发性肾病综合征的研究进展
- Author:
Yuanzhao ZHI
1
;
Lu CAO
;
Jianjiang ZHANG
Author Information
1. 郑州大学第一附属医院儿科，河南省儿童肾脏病临床诊疗中心，郑州 450052
- Keywords:
Primary nephrotic syndrome;
Child;
Anti-CD 20 monoclonal antibodies
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(23):1833-1836
- CountryChina
- Language:Chinese
-
Abstract:
Primary nephrotic syndrome (PNS) is one of the common glomerular diseases in children.Glomerular disease treatment by anti-CD 20 monoclonal antibodies is currently a hot topic.There are three generations of anti-CD 20 monoclonal antibodies.As a representative of the first generation of anti-CD 20 monoclonal antibodies, Rituximab (RTX) has been proven effective in treating children with steroid-dependent/frequent-relapsing nephrotic syndrome (SDNS/FRNS). Ofatumumab (OFA) and Obinutuzumab (OBI) represent the second-and the third-generation anti-CD 20 monoclonal antibodies, respectively.OFA and OBI have showed good efficacy and safety in pediatric PNS.In this paper, clinical studies and applications of anti-CD 20 monoclonal antibodies in the treatment of children with PNS were reviewed, so as to provide a reference for the treatment of PNS in children.
